BioDelivery Sciences International, Inc. to Participate in BioMilano 2003
Company Will Showcase BioGeode(TM) and Bioral(R) Drug and Micronutrient Delivery
Systems In New Markets
NEWARK, N.J., Nov. 11 /PRNewswire-FirstCall/ -- BioDelivery Sciences
International, Inc. announced today its participation in the BioMilano 2003
Italian Partnering Conference in Milan, Italy on November 21, 2003. BioMilano
2003 is a showcase for Italian financial institutions and pharmaceutical
industry members. BioDelivery Sciences International was invited to present at
this prestigious event through its relationship with Sigma Tau, one of Italy's
top pharmaceutical companies and a sponsor of the event.
According to Raphael J. Mannino, PhD., Chief Scientific Officer and Executive
Vice President of BioDelivery Sciences International, Inc, by presenting at this
one-day intensive conference, BDSI will gain access, exposure and contacts in
both the financial and pharmaceutical markets in Italy.
BioDelivery Sciences International, Inc.'s licensed and patented Bioral(R)
cochleate pharmaceutical delivery system and proprietary BioGeode(TM) nutrient
and flavoring delivery system for food, beverage and personal care applications,
have global market potential and represent a strong pipeline for current and
future development.
"Accordingly, the timing of the BioMilano 2003 presentation couldn't be better,"
Dr. Mannino said, "Italy has demonstrated great potential for international
exploration in the pharmaceutical industry, and BDSI is positioning itself there
for potential investment and partnering opportunities." Bioral(TM) Amphotericin B, a cochleate preparation of a powerful anti- fungal
agent, is one of BDSI's lead pharmaceutical projects. This preparation
showcases one of the many advantages of the Bioral(R) cochleate delivery system:
Toxic drugs which were previously only available by injection have been
demonstrated to be readily and effectively deliverable in a stable, safe and
orally bio-available formulation.
The new BioGeode(TM) delivery system has an enhanced protective structure that
can be employed to stabilize and deliver a wide range of micronutrients and has
the potential to increase the nutritional value of processed foods and
beverages. It also has potential and wide-ranging applications in personal care
products and for the delivery of difficult to work with water-insoluble
compounds such as hydrophobic drugs, antioxidants and oils. Micronutrients
formulated into BioGeodes(TM) are stabilized and protected from the potentially
harsh conditions of food processing and product manufacturing and also exhibit
extended shelf life. The lead product employing the BioGeode(TM) delivery system
is an antioxidant preparation which has been manufactured in kilogram quantities
using standard, cost-effective manufacturing protocols.
Both the BioGeode(TM) and Bioral(R) Delivery Systems are manufactured from safe,
naturally occurring phospholipid and calcium that form a protective barrier
around the drug or nutrient being introduced into the body. In January 2003,
BDSI formed a majority-owned subsidiary, Bioral Nutrient Delivery, LLC, or BND,
in order to exploit the potential of BDSI's core licensed technologies in the
delivery of fragile micronutrients into the body. Effective April 1, 2003, all
applications of BDSI's technology for the human and animal food and beverage
processing and personal care product opportunities were licensed to BND, and the
BioGeode(TM) technology will fall under this license for these applications.
BioDelivery Sciences International, Inc. is a biotechnology company that is
developing and seeking to commercialize a patented delivery technology designed
for a potentially broad base of pharmaceuticals, vaccines, over-the- counter
drugs, and nutraceuticals and, through its subsidiary, Bioral Nutrient Delivery,
LLC, micronutrients in processed foods and beverages and personal care
products.
Note: Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties. Such statements are subject to certain factors, which may cause
the Company's results to differ. Factors that may cause such differences
include, but are not limited to, the Company's ability to accurately forecast
the demand for each of its licensed technology and products associated
therewith, the gross margins achieved from the sale of those products and the
expenses and other cash needs for the upcoming periods, the Company's ability to
obtain raw materials from its contract manufacturers on a timely basis if at
all, the Company's need for additional funding, uncertainties regarding the
Company's intellectual property and other research, development, marketing and
regulatory risks and certain other factors that may affect future operating
results and are detailed in the company's filings with the Securities and
Exchange Commission.
L.G. Zangani, LLC provides financial public relations service to the Company. As
such L.G. Zangani, LLC and/or its officers, agents and employees, receives
remuneration for public relations and or other services in the form of monies,
capital stock in the Company, warrants or options to purchase capital in the
Company. DATASOURCE: BioDelivery Sciences International, Inc.
CONTACT: Francis E. O'Donnell, Jr., M.D., President and CEO of BioDelivery Sciences International, Inc., +1-973-972-0015; or Dawn Moore of L.G. Zangani, LLC, +1-908-788-9660 Web site: http://www.biodeliverysciences.com/
|